Skip to main content
AIDS (London, England)
Absolute or total lymphocyte count as a marker for the CD4 T lymphocyte criterion for initiating antiretroviral therapy.
The pavia consensus statement.
HIV therapy in 2003: consensus and controversy.
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.
A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection.
To stop or not to stop: that is the question, but what is the answer?
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression.
